Recently, in addition to the PD-L1 level and tumor mutational burden (TMB), several novel molecular mutations, such as KRAS/TP53 mutations, BRAF mutations, LKB1/STK11 mutations etc., presented predictive value (30–32). The gene discussed is KRAS; the disease is neoplasm.